Targeting the perpetrator: breast cancer stem cell therapeutics.
The hypothesis that tumors may originate from a rare population of cancer stem cells (CSCs) has gained tremendous popularity in recent years and is supported extensively by several pioneering works. Cancer therapies targeting CSCs have unlimited potential for relapse free survival of cancer patients. As a result, knowledge of biological pathways that govern CSCs is very important and this review is focused on the biology of CSCs with special emphasis on breast CSCs, and recent advances in therapeutic approaches targeting them.
Pal
Arindam
A
The University of Kansas Medical Center, 3901 Rainbow Blvd, Lied G015, Kansas City, KS, 66160, USA.
Valdez
Kelli E
KE
Carletti
Martha Z
MZ
Behbod
Fariba
F
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D016513:Mice, SCID; D008822:Mice, Transgenic; D035683:MicroRNAs / Q000378:metabolism; D058990:Molecular Targeted Therapy; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D015398:Signal Transduction; D059016:Tumor Microenvironment
D000970:Antineoplastic Agents; D035683:MicroRNAs